Item 7.01 Regulation FD Disclosure.
As previously disclosed, on March 23, 2022, Ligand Pharmaceuticals, Incorporated
(“Ligand”) and Avista Public Acquisition Corp. II, a Cayman Islands exempted
company (“APAC”), entered into certain definitive agreements providing for a
combination of APAC and OmniAb, Inc., Ligand’s antibody discovery business, and
a Delaware corporation and wholly owned subsidiary of Ligand (“OmniAb”).
Attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
into this Item 7.01 by reference is an analyst teach-in presentation used by
APAC and OmniAb in connection with their proposed business combination.
In accordance with General Instruction B.2. of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liability of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 OmniAb analyst teach-in presentation dated June 21, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses
postbrexitcompliance.com 